Interview with our CEO Kristina Torfgård in BioStock

Date: 2023-01-13

Alzinova's CEO Kristina Torfgård was interviewed about the accelerated approval of lecanemab

FDA (Food and Drug Administration) approved Eisais/Biogens lecanemab for the treatment of Alzheimer’s disease via an accelerated procedure. The approval is based on data from a phase 2b study in early Alzheimer’s disease, which showed that the candidate reduced the accumulation of the harmful protein amyloid-beta, so-called plaques, in the brain. BioStock interviewed Kristina about the accelerated approval of lecanemab.

Read the interview (in Swedish)